24HourWire
News from all angles
STAT News
Center
STAT+: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem
Alnylam is heavily dependent on its heart drug Amvuttra for growth — and sales have been slowing.